MedPath

Effect of Heatwaves on Glycemic Control in People With Type 1 Diabetes Treated With Artificial Pancreas

Completed
Conditions
Type 1 Diabetes
Interventions
Device: advanced hybrid closed-loop
Registration Number
NCT06214780
Lead Sponsor
Castilla-La Mancha Health Service
Brief Summary

To analyze the effect of heatwaves on interstitial glucose in adult patients with type 1 diabetes mellitus treated with artificial pancreas

Detailed Description

Observational retrospective study to analyze the effect of heatwaves on interstitial glucose in adult patients with type 1 diabetes mellitus treated with advanced hybrid closed-loop systems in the Castilla-La Mancha region (southcentral Spain). Main objective is the difference in time in range of intersticial glucose between 3.0-10 mmol/L (70-180 mg/d) measured throught real-time continuous glucose monitoring during the two consecutive greatest heatwave during summer 2024 (5th-26th August) comparted to the following period (27th August to 17th September). Data analysis is conducted using SPSS (Chicago, IL) statistics software. Results are presented as mean ± SD values or percentages. A paired Student's t-test or a Wilcoxon signed-rank test were used for the analysis of differences. Comparisons between proportions were analyzed using a chi-squared test. A P value \< 0.05 was considered statistically significant. The protocol was approved by the reference Castilla-La Mancha Public Health Institute Ethic Committee.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
193
Inclusion Criteria
  • Type 1 diabetes
  • Older than 18 years old
  • Using advanced hybrid closed-loop systems (AHCL)
  • Paired active AHCL data from the heatwave periods and two consecutive weeks
Exclusion Criteria
  • Younger than 18 years old
  • Not using AHCL
  • Not having active paired AHCL data from the analyzed periods

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Type 1 diabetes patientsadvanced hybrid closed-loopAdult patients treated with advanced hybrid closed-loop in Castilla-La Mancha during summer 2023.
Primary Outcome Measures
NameTimeMethod
Change in time in range14 days

Change in Time in range (TIR) 3.0-10 mmol/L (70-180 mg/d) of interstitial glucose from the heatwaves period to 14 days after its end

Secondary Outcome Measures
NameTimeMethod
Change in Coefficient of variation percentage (CV)14 days

Change in Coefficient of variation percentage of interstitial glucose from the heatwaves period to 14 days after its end

Change in Time below range 2 (TBR2)14 days

Change in Time bellow range \<3 mmol/L (\<54 mg/dL) of the interstitial glucose from the heatwaves period to 14 days after its end

Change in Time in hypoglycemia14 days

Change in Daily time in hypoglycemia (\<3.9 mmol/L, \<70 mg/dL) of interstitical glucose from the heatwaves period to 14 days after its end

Change in Time below range 1 (TBR1)14 days

Change in Time bellow range \<3.9 mmol/L (\<70 mg/dL) of the interstitial glucose from the heatwaves period to 14 days after its endfrom the heatwave period to 14 days after its end

Change in Percentage of time of varibles modes of automatization14 days

Change in Percentage of time of varibles modes of automatization (temporal objective, sleeping mode, exercise mode) from the heatwaves period to 14 days after its end

Change in Time above range 1 (TAR1)14 days

Change in Time above range \>10 mmol/L(\>180 mg/dL) of the interstitial glucose from the heatwaves period to 14 days after its end

Change in Glucose management index14 days

Change in Glucose management index of interstitial glucose from the heatwaves period to 14 days after its end

Change in Percentage of patients attaining the the International Consensus on Time in Range (ICTR) goals14 days

Change in Percentage of patients (from total) attaining TIR\>70%, TBR1\<4%, TBR2\<1%, TAR1\<25%, TAR2\<5% and CV \<36% from the heatwaves period to 14 days after its end

Adherence to advaced hybrid closed-loop14 days

Change in Time of use automatization of advanced hybrid closed-loop (% possible time of use) from the heatwaves period to 14 days after its end

Change in Time above range 2 (TAR2)14 days

Change in Time above range \>13.9 mmol/L (\>250 mg/dL) of the interstitial glucose from the heatwaves period to 14 days after its end

Trial Locations

Locations (9)

Virgen del Prado Hospital

🇪🇸

Talavera De La Reina, Toledo, Spain

Albacete University Hospital

🇪🇸

Albacete, Spain

Guadalajara University Hospital

🇪🇸

Guadalajara, Spain

Ciudad Real General University Hospital

🇪🇸

Ciudad Real, Spain

Virgen de la Luz University Hospital

🇪🇸

Cuenca, Spain

Toledo University Hospital

🇪🇸

Toledo, Spain

Valdepeñas General Hospital

🇪🇸

Valdepeñas, Ciudad Real, Spain

La Mancha-Centro Hospital

🇪🇸

Alcázar De San Juan, Ciudad Real, Spain

Santa Barbara Hospital

🇪🇸

Puertollano, Ciudad Real, Spain

© Copyright 2025. All Rights Reserved by MedPath